

Press Release

For Immediate Distribution

Panacea Biotec Announces Collaboration with a leading International Pharmaceutical Company

New Delhi: December 24, 2014: Panacea Biotec, one of India's leading research based health management companies has entered into collaboration with a leading International Pharmaceutical Company for the development and supply of an immunosuppressant generic product in USA.

The key highlights of the collaboration are as follows:

The collaboration has been established on 23rd Dec 2014; for the research, development and subsequent ANDA submission by Panacea Biotec for a generic immunosuppressant drug. Under the terms of the agreement, Panacea Biotec shall receive an upfront Research Fee, as well as milestone payments linked with the development of the product.

Upon commercialization of the product; Panacea Biotec shall be responsible for manufacturing and supply of the product to the partner company, while the partner would be responsible for front end sales and distribution. Both companies have agreed on a hybrid model of transfer price and profit share at a pre-agreed ratio.

Commenting on the development, Dr. Rajesh Jain, Joint Managing Director, Panacea Biotec Ltd. said "This collaboration is an excellent example where two organization leverage each others strengths and resources in a highly synergistic manner to achieve a shared objective. Commercialization of products at a global scale and especially in USA has been a forte of our partner company, while developing complex immunosuppressant drugs with end to end alignment of facilities and infrastructure has been a strong point of Panacea Biotec."

About Panacea Biotec

Panacea Biotec is one of India's leading research-based pharma-biotech companies with established research, manufacturing and marketing capabilities. Panacea Biotec is one of the largest vaccine producer in India and has been amongst the top 40 biotechnology companies (Bio Spectrum – ABLE Survey, July 2014) and the top 60 pharmaceutical companies (AIOCD AWACS – MAT May 2014) in India. The product portfolio of Panacea Biotec includes innovative products in therapeutic areas of oncology, organ transplantation, nephrology, diabetes,



osteoporosis, cardiovascular diseases and paediatric immunization vaccines. Panacea Biotec is working on a robust pipeline of high barrier to entry generics and 505(b)(2)s, thus leveraging its capabilities in the areas of nanotechnology and platform drug delivery technologies like microparticles, liposomes, gastroretentive systems. Panacea Biotec has introduced its products in 22 countries across the world including USA and Germany through a combination of strategic collaborations and direct presence in select geographies. The company has research collaborations with leading national and international research organizations and corporations. The company's state of the art manufacturing facilities for vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. The company has around 2900 employees including around 100 scientists working across 4 R&D centers of the company.

For more information, please contact –



Mr. P. D. Karan
GM - Business Diversification & Corporate Communication



B-1 Extn. / A-27, Mohan Co-Operative Industrial Estate,
Mathura Road, New Delhi – 110044, INDIA
Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct)
Fax + 91 11 41578002
Mobile: + 91 9312693040
Email: pdkaran@panaceabiotec.com
Web: www.panaceabiotec.com